OTLC (Oncotelic Therapeutics) Insider Ownership: 7.70 % (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Oncotelic Therapeutics Insider Ownership?

Oncotelic Therapeutics OTLC +41.49% Insider Ownership is 7.70 % as of Aug. 14, 2026. The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oncotelic Therapeutics's insider ownership is 7.70%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oncotelic Therapeutics's Institutional Ownership is 0.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oncotelic Therapeutics's Float Percentage Of Total Shares Outstanding is 65.15%.

Oncotelic Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Oncotelic Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncotelic Therapeutics Insider Ownership Chart

Oncotelic Therapeutics Historical Data

The historical data trend for Oncotelic Therapeutics can be seen below:

2018-02-28 2018-03-31 2018-04-30 2018-05-31 2018-06-30 2018-07-31 2018-08-31 2018-09-30 2018-10-31 2018-11-30
Insider Ownership 8.44 8.44 8.44 7.70 7.70 7.70 7.70 7.70 7.70 7.70

Oncotelic Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 7.70 % mean?
Oncotelic Therapeutics (OTLC) has a Insider Ownership of 7.70 % as of Aug. 14, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Oncotelic Therapeutics and its competitors.
Is Oncotelic Therapeutics' Insider Ownership too high?
Oncotelic Therapeutics' current Insider Ownership is 7.70 %.
How does Oncotelic Therapeutics' Insider Ownership compare to KTTA and LSTA?
Oncotelic Therapeutics' Insider Ownership of 7.70 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Oncotelic Therapeutics and its competitors. Oncotelic Therapeutics's current Insider Ownership is 7.70 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current Insider Ownership of 7.70 %. The current Insider Ownership is 7.70 %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current Insider Ownership is 7.70 % as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncotelic Therapeutics Business Description

Address 29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.